CAH Q1 FY27 earnings call: key takeaways

• EPS of $3.26 beat the $2.92 consensus and revenue of $67.5 billion exceeded the $66.5 billion consensus (3:44)
• The company raised fiscal 2027 EPS guidance to $12.80 to $13.00 from $12.40 to $12.60. (3:44)

Results vs expectations

What changed since last quarter

• Raised fiscal 2027 EPS guidance to $12.80 to $13.00 from $12.40 to $12.60. (3:44)
• Raised guidance for the pharma segment's profit growth to 10% from 8% to 11%. (9:14)

What analysts pressed on

• Whether the 340B reimbursement changes will impact provider space and MSOs. (30:36)
• Concerns about the impact of the OPPS rule on provider space and volume shifts. (30:36)

In their words

• We are doing what we said we would do and we are operating with clear strategic and financial priorities. Aaron Alt (12:10)
• We saw strong demand in the first quarter, and indeed, our guidance going forward assumes that strong demand persists into the rest of the year. (21:52)
• We have a long-standing record of constructive engagement with policymakers on both sides. Jason (1:33)
• We are pleased with our progress and continue to focus on building durable improvements to items below the line. Aaron Alt (3:44)